What Имигран Treats: Main Uses and Benefits

Имигран is relevant for managing conditions characterized by periods of heightened symptoms such as migraine attacks (with or without aura). The medicine is commonly used in areas where short-term symptomatic assistance is needed to address the progression of an acute episode. It is also relevant in conditions characterized by periods of heightened symptoms, such as cluster headaches.

Symptom Relief and Benefit

Имигран helps address symptom clusters that may become intense or disruptive, including the main headache pain, nausea, vomiting, and heightened sensitivity to light and noise. It provides supportive relief when symptoms interfere with daily functioning and may assist with maintaining functional stability during an acute episode.

“The medicine is commonly used across domains where additional symptomatic support is needed to ease the overall burden of distressing manifestations.”

Quick Fact: Relief for Severe Episodes
This medication is primarily relevant when symptoms are severe or rapidly escalating. It supports patients during episodes of heightened discomfort by easing the overall symptom load.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Status

Имигран is strictly contraindicated for populations with existing cardiovascular or cerebrovascular instability. Patients must not use this medicine if they have a history or signs of Ischemic Coronary Artery Disease (CAD), including myocardial infarction or angina, uncontrolled or severe high blood pressure (hypertension), specific heart rhythm disorders such as Wolff-Parkinson-White syndrome, or a history of stroke or Transient Ischemic Attack (TIA). Use is also prohibited in patients with severe hepatic impairment (severe liver disease).

Eligibility is restricted by age: the medicine is not recommended for individuals under 18 years of age or for older adults over 65 years. This is due to regulatory findings that safety and efficacy are either not established or clinical experience is limited in these age groups.

In other populations, use may be conditional. Patients with multiple cardiovascular risk factors (e.g., diabetes, hypercholesterolemia) require a prior cardiovascular evaluation. The medicine should be used with caution in patients with mild to moderate hepatic impairment or a history of seizures. For pregnancy, use is generally not recommended unless clearly necessary. Breastfeeding mothers are advised to interrupt feeding for 12 hours after a dose to minimize infant exposure.

The official regulatory profile for Имигран (Sumatriptan) is defined by mandatory restrictions on co-administration with specific medicinal product classes. These constraints are based on documented risks of pharmacokinetic or pharmacodynamic interactions.

Interaction Scope

Meditinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Ergot-containing medicines/Ergot derivatives, and other 5-HT₁ Receptor Agonists (Triptans).

Specific interacting medicines (if explicitly listed): Ergotamine, Methysergide, and other Triptans.

Mechanistic basis of interactions (only if stated in label): Inhibition of the primary metabolic enzyme, Monoamine Oxidase-A (MAO-A), and pharmacodynamic reinforcement leading to additive vasoconstriction or Serotonin Syndrome risk.

Timing-based interaction rules (if applicable): A 14-day washout period is required after discontinuation of an MAOI before administering Sumatriptan. A 24-hour separation is required between the administration of Sumatriptan and ergotamine-containing or ergot-type drugs.

Population-specific interaction notes (if applicable): Patients with hepatic impairment have a heightened potential for increased systemic exposure and reduced clearance, which may intensify drug-drug interactions.

Interaction-related restrictions: Strictly prohibited co-administration with MAOIs, ergot derivatives, and other 5-HT₁ Receptor Agonists.

Interaction Classifications (High-level)

Interaction severity classification (as defined in official documents): Contraindicated for combinations involving MAOIs, ergot derivatives, and other triptans, and a Serious interaction risk with other serotonergic agents like SSRIs/SNRIs.

Regulatory basis: All classifications and restrictions are based on official government documents, including FDA Prescribing Information and EMA/MHRA Summary of Product Characteristics.

Connection to the overall interaction profile: The regulatory documentation prohibits combinations that interfere with the drug's MAO-A metabolic clearance or that produce synergistic vasoconstriction. These label-based restrictions establish strict administration constraints and define a serious interaction risk with co-administered serotonergic medications.

Dual Mechanism of Action on Serotonin mathbf5 -mathbfHT1 Receptors

Имигран (Sumatriptan) exerts its function through selective agonism on the mathbf5 -mathbfHT1 B and mathbf5 -mathbfHT1 D receptor subtypes, engaging mechanisms that modulate the neurovascular cascade. This targeted molecular interaction initiates two simultaneous physiological changes: modulation of cranial vascular tone and inhibition of afferent sensory signaling.

---

Modulation and Inhibition

The drug's activation of mathbf5 -mathbfHT1 B receptors on the smooth muscle of intracranial extracerebral blood vessels induces contraction of the tissue. This focused action engages pathways involved in regulating the excessive dilation of these vessels, contributing to the modulation of activity within the cranial pathways. Simultaneously, mathbf5 -mathbfHT1 D receptors found on the terminals of the trigeminal nerves are activated, resulting in presynaptic inhibition. This mechanism restricts the release of vasoactive neuropeptides, particularly CGRP, which results in a dampening of excessive mediator activity and modification of the downstream signaling cascade.

Имигран (Sumatriptan) is used exclusively for the acute treatment of specific severe headaches and is not indicated for preventative use. The officially approved routes of administration include oral (tablets), subcutaneous (SC) injection, and intranasal (spray), offering administration versatility depending on the clinical scenario.

Official Dosing and Administration

The medication is intended for as-needed use, with the initial dose administered as early as possible after the onset of the acute episode. Standard adult dosing regimens vary by form: oral doses typically range from 25 mg to 100 mg, while the SC injection is commonly 4 mg or 6 mg for migraine, or 6 mg for cluster headache. The total dose must be strictly adhered to within any 24-hour period, with the cumulative dose for the oral form capped at 200 mg. Oral tablets may be taken with or without food and must be swallowed whole, not crushed or chewed.

Redosing and Procedural Constraints

If the headache returns after initial relief, strict time intervals govern repeat dosing. A second oral or nasal dose may be taken after at least 2 hours, whereas a second SC dose may be administered after at least 1 hour. Critically, a second dose must not be taken for the same attack if the first dose provided no response. The safety of treating an average of more than four headaches in a 30-day period has not been established.

For specific populations, official dose adjustments apply. For instance, the maximum single oral dose should not exceed 50 mg in patients with mild to moderate hepatic impairment. The use of the medication is generally not recommended for individuals under 18 or over 65 years of age, as safety and effectiveness are not established in these age groups.

Research evidence / Overview of studies for Имигран

This overview is a summary of the clinical evidence used to support the acute treatment indications for Имигран (Sumatriptan). The information focuses on the types of studies conducted, the research outcomes that were explored, and what remains unclear in the evidence landscape, without offering clinical guidance or recommendations.

Evidence Base for Acute Treatment of Migraine Attacks

Research exploring the use of Имигран for acute migraine attacks is primarily based on numerous short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptom intensity or variability changes over a defined time interval following administration. The trials were applied in studies examining patient-reported experiences related to physical discomfort and outcomes describing episodic or acute changes in conditions associated with acute or disruptive episodes.

Evidence Base for Acute Treatment of Cluster Headaches

Due to the nature of cluster headache attacks, research explored outcomes related to physical discomfort at very short time intervals, often less than 30 minutes after treatment. The evidence base for the use of Имигран in conditions characterized by periods of heightened symptoms, specifically cluster headaches, is mainly derived from shorter, focused clinical trials, primarily utilizing the subcutaneous injection form.

Study Duration and Long-Term Observation

The core clinical trials for Имигран are designed to evaluate responses during a single, acute episode, meaning the primary follow-up durations were limited, usually focusing on short-term symptom patterns up to 24 hours. The research evidence contributes to the description of symptom patterns during this acute phase. Long-term effects and the consistency of response during long-term repeated use are not fully established by the initial, short-duration RCTs.

Consistency of Findings and Research Gaps

The overall evidence base for the acute treatment of migraine in adults is composed of a significant number of studies in headache management. The results apply only to the populations studied in the RCTs, and data for certain groups, such as older adults, remain insufficient. Comparative evidence is lacking for the outcomes measured when comparing different formulations against each other in real-world settings. Research is ongoing to provide further insight into short-term changes.

Key Studies & References NIH MedlinePlus Drug Information: Sumatriptan

Common questions about Имигран (FAQ)

Q: Is Имигран a type of painkiller?

A: No, official product information describes Имигран (Sumatriptan) as a targeted, specialized medication, not a general pain reliever. It belongs to a class of drugs called triptans and is used only for the acute treatment of specific severe headaches. Regulatory documents state that it is generally described as having no effect on pain other than from migraines or cluster headaches.

Q: How does Имигран differ from regular headache medicines?

A: The key difference is in its mechanism of action. Official sources state that Имигран works by selectively targeting certain serotonin receptors on cranial blood vessels and nerve endings to address the specific neurovascular changes thought to be associated with severe headaches. This positions it differently from standard, over-the-counter headache medicines, which often reduce general inflammation or block pain signals.

Q: Is it true that Имигран is only effective if taken early in an attack?

A: Regulatory documents advise that the medication is most often administered as early as possible after the onset of an acute attack. However, some regulatory sources describe it as having effects regardless of the stage of attack it is administered, but individual outcomes may vary.

Q: Is there a maximum number of days per month Имигран should be used?

A: Official documentation notes that frequent use may be associated with the development of Medication Overuse Headache (MOH), where the headache can become worse or more frequent. Some regulatory documents suggest that the risk increases when the medication is used for 10 or more days per month.

Q: Are the side effects of Имигран usually mild or severe?

A: Official safety tables list effects that range from common, often transient sensations like tingling or dizziness, to rare but serious risks. Serious adverse reactions are reported primarily from post-marketing surveillance, while transient sensations are listed as common treatment-emergent events.

Q: Does Имигран cause drowsiness or make you tired?

A: Drowsiness (somnolence) and dizziness are explicitly listed in regulatory documents as common adverse reactions. These effects are mentioned in official safety warnings.

Q: What is the difference in how the tablet and the nasal spray work?

A: All formulations contain the same active ingredient, but the difference is in the route of administration and the resulting rate of absorption. The nasal spray and subcutaneous injection forms are absorbed faster than the oral tablet. This difference in delivery method results in varied absorption rates and times to peak concentration.

Q: Can Имигран interact with herbal supplements or over-the-counter vitamins?

A: Official regulatory documents specifically note an increased potential for undesirable effects when triptans are used along with certain herbal preparations containing St John’s Wort (Hypericum perforatum). Official documentation notes the risk and lists a specific herbal preparation for caution.

Q: Can Имигран affect liver or kidney function?

A: Yes, official documentation states the product is strictly contraindicated (must not be used) in patients with severe hepatic (liver) impairment. Furthermore, some combined products containing sumatriptan are also contraindicated for use in patients with severe renal (kidney) impairment.

Q: Can Имигран be used for tension headaches or just migraines?

A: Regulatory documents indicate that the medication is specifically approved for the acute treatment of migraine attacks (with or without aura) and for cluster headaches, depending on the formulation. It is not indicated for the treatment of common tension-type headaches.

Q: How long does it typically take for Имигран to start working?

A: According to clinical information, the time to therapeutic effect varies significantly depending on the form used. For oral tablets, peak concentrations are reached in about two hours, with therapeutic effects typically noted within three hours of administration, while injection and nasal spray forms often have a faster onset.

Q: What happens if Имигран is taken when a headache is already severe?

A: Official guidelines emphasize taking the medication as early as possible after the onset of an acute attack. Regulatory documentation contains constraints stating that if an individual does not respond to the first dose of the medication, the instruction is not to take a second dose for the same attack.

Q: Why are there different strengths or doses of Имигран?

A: Different strengths (e.g., 25, mg, 50, mg, and 100, mg oral tablets) are provided to accommodate individual patient needs. Regulatory documents explain that the severity of attacks varies, and some individuals may require a higher dose than the starting dose to achieve the intended therapeutic effect.

Q: Does the effectiveness of Имигран decrease over time?

A: While regulatory documents do not directly address drug tolerance, they caution about a safety pattern known as Medication Overuse Headache (MOH). This condition occurs when frequent or prolonged use can paradoxically lead to the worsening of headache symptoms.

Q: What is the difference between brand-name Имигран and generic versions?

A: The brand-name product Имигран (Imitrex) and its generic counterparts, which are named Sumatriptan, contain the exact same active ingredient. Generic versions that are approved by regulatory bodies (like the FDA) are determined to be bioequivalent to the brand-name drug.

Q: What are the signs of a serious allergic reaction to Имигран?

A: Official documents warn that serious hypersensitivity reactions, including anaphylaxis (a severe, whole-body reaction) and angioedema (severe swelling of the face, tongue, or throat), have been reported. Signs may also include difficulty breathing, wheezing, or skin rash/hives.

Q: Is Имигран known to affect vision or eye health?

A: Regulatory safety documents mention that rare cases of transient visual disturbances, including changes in vision, have been reported following the use of this medication.

Q: What is the regulatory status of Имигран (e.g., approved by FDA/EMA)?

A: Имигран (Sumatriptan) is an approved prescription-only medicine for its specific acute uses in adults. Its status and safety are overseen by major government regulatory bodies worldwide, including the FDA and the EMA.

Q: Are there specific warnings about driving or operating machinery while using Имигран?

A: Yes, official warnings state that both the severe headache itself and treatment with Имигран may cause symptoms like drowsiness or dizziness. Official warnings state that these effects may impact the ability to perform skilled tasks, such as driving or operating machinery.

Q: Does Имигран help with the nausea and light sensitivity associated with migraines?

A: Clinical information indicates that in addition to relieving the headache pain, the drug often helps to relieve other symptoms that commonly occur with migraines. This includes associated symptoms like nausea, vomiting, and sensitivity to light or sound.

Q: What is the evidence regarding Имигран's use in chronic migraines?

A: The drug's official indications, according to regulatory documents, are for the acute treatment of migraine attacks (episodic). Имигран is not indicated for the prevention or prophylactic treatment of migraines, which is generally required for the management of chronic forms.

Q: Is Имигран habit-forming or addictive?

A: While standard regulatory labels do not typically classify the medication as 'addictive' or 'habit-forming,' the safety information does prominently document the risk of Medication Overuse Headache (MOH). MOH is a condition that occurs with the frequent use of acute headache treatments.

Q: Why do some people get a bitter taste after using the nasal spray form?

A: The regulatory documents for the nasal spray formulation list an unusual or bad taste (dysgeusia) as a common adverse event. This is generally a localized reaction following the administration of the medicine through the nose.

Q: Can men and women use Имигран equally?

A: The drug is officially approved for use in adults generally, and regulatory documents do not specify restrictions based on sex. However, specific restrictions and warnings do apply to women who are pregnant or breastfeeding.

Q: Is Имигран used internationally under different names?

A: Yes, official product information confirms that the drug with the active ingredient Sumatriptan is marketed in different countries under various brand names. These include, but are not limited to, Имигран or Imitrex.

How to Store and Dispose of Имигран (Sumatriptan)

Official regulatory documents define strict environmental conditions for the storage of Imigran to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Prohibited	Do not freeze. Keep away from excessive heat and moisture (e.g., do not store in the bathroom).
Protection	Keep the product in the original container, tightly closed, and away from direct light.
Safety	Keep Imigran out of the reach and sight of children.

Disposal Instructions

Regulatory guidance directs that unused or expired Imigran should not be flushed down the toilet or poured down a sink. Instead, dispose of the medicine by utilizing a drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance, seal it in a container, and place it in the household trash. Used injection needles and syringes must be disposed of immediately in an approved sharps container.